• By ICR Secretariat
  • Posted Thursday, March 31, 2022

Stalicla completes phase 1b trials into precision medicine for autism spectrum disorder


STP1 has demonstrated good safety and tolerability profiles, while also showing positive results for neurological function

Swiss clinical stage biotech company, Stalicla, has announced the highly successful completion of phase 1b trials for its lead drug candidate, STP1.